ERBB2 and breast carcinoma: Pilaralisib was assessed in phase II clinical trials for endometrial cancers by monotherapy, as well as in patients with breast cancers in conjunction with HER2 antagonist trastuzumab or aromatase inhibitor, letrozole [101].